WO2014128568A2 - Compositions et procédés destinés au traitement de l'hépatite c - Google Patents

Compositions et procédés destinés au traitement de l'hépatite c Download PDF

Info

Publication number
WO2014128568A2
WO2014128568A2 PCT/IB2014/000815 IB2014000815W WO2014128568A2 WO 2014128568 A2 WO2014128568 A2 WO 2014128568A2 IB 2014000815 W IB2014000815 W IB 2014000815W WO 2014128568 A2 WO2014128568 A2 WO 2014128568A2
Authority
WO
WIPO (PCT)
Prior art keywords
vlp
protein
polypeptide
hcv
gag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/000815
Other languages
English (en)
Other versions
WO2014128568A3 (fr
Inventor
David E. Anderson
David Klatzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of WO2014128568A2 publication Critical patent/WO2014128568A2/fr
Publication of WO2014128568A3 publication Critical patent/WO2014128568A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV). HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment and transfusions. More than
  • HCV cytotoxic T lymphocytes
  • the present invention provides methods and compositions useful for prophylaxis, therapeutic treatment, and/or study of chronic viral infections exemplified by HCV.
  • the present invention provides virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more viral epitopes, such as, for example, from HCV envelope glycoproteins El and/or E2 and/or non-structural proteins such as NS3 and/or NS4A.
  • VLPs virus-like particles
  • MMLV Moloney Murine leukemia virus
  • provided VLPs contain one or more epitopes from internal viral proteins (e.g., HCV non-structural proteins such as NS3 and/or NS4A) which are antigens that play a role in induction of cellular immune responses (e.g., T-cell response).
  • utilized viral internal proteins e.g., non-structural proteins such as NS3 and/or NS4A
  • CTL cytotoxic T lymphocytes
  • the present invention provides fusion proteins of a Gag polypeptide and one or more internal non-structural viral proteins.
  • Figure 5 shows Coomasie Blue Staining of SDS PAGE of exemplary monovalent and bivalent eVLPs formed from expression plasmids for E2-G and Gag or Gag/NS3-NS4A.
  • Figure 6 shows Western Blot Detection of Gag Protein in exemplary monovalent and bivalent eVLPs formed from expression plasmids for E2-G and Gag or Gag/NS3-NS4A.
  • Nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
  • synthetic amino acid encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and/or substitutions.
  • Amino acids, including carboxy- and/or amino-terminal amino acids in peptides can be modified by methylation, amidation, acetylation, protecting groups, and/or substitution with other chemical groups that can change the peptide's circulating half-life without adversely affecting their activity. Amino acids may participate in a disulfide bond.
  • Characteristic sequence is a sequence that is found in all members of a family of polypeptides or nucleic acids, and therefore can be used by those of ordinary skill in the art to define members of the family.
  • Extracellular domain As is known in the art, polypeptides sometimes have transmembrane, cytoplasmic, and/or extracellular domains. In general, an "extracellular domain", as used herein, refers to a domain that has an attribute of being present outside a cell. As will be appreciated, it is not required that every amino acid in an extracellular domain be present outside the cell. For example, in some embodiments, an extracellular domain is characterized in that a designated stretch or portion of a protein is substantially located outside the cell. As is well known in the art, amino acid or nucleic acid sequences may be analyzed using a variety of algorithms to predict protein subcellular localization (e.g., extracellular localization). Exemplary such programs include psort (PSORT.org), Prosite
  • Fusion protein generally refers to a polypeptide including at least two segments, each of which shows a high degree of amino acid identity to a peptide moiety that (1) occurs in nature, and/or (2) represents a functional domain of a polypeptide.
  • a polypeptide containing at least two such segments is considered to be a fusion protein if the two segments are moieties that (1) are not included in nature in the same peptide, and/or (2) have not previously been linked to one another in a single polypeptide, and/or (3) have been linked to one another through action of the hand of man.
  • the term “gene” may include gene regulatory sequences ⁇ e.g., promoters, enhancers, etc.) and/or intron sequences. It will further be appreciated that definitions of gene include references to nucleic acids that do not encode proteins but rather encode functional RNA molecules such as tRNAs, RNAi-inducing agents, etc.
  • the term “gene” generally refers to a portion of a nucleic acid that encodes a protein; the term may optionally encompass regulatory sequences, as will be clear from context to those of ordinary skill in the art. This definition is not intended to exclude application of the term “gene” to non-protein- coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a protein-coding nucleic acid.
  • Gene product or expression product As used herein, the term “gene product” or
  • expression product generally refers to an R A transcribed from the gene (pre-and/or postprocessing) or a polypeptide (pre- and/or post-modification) encoded by an RNA transcribed from the gene.
  • heterologous refers to a protein or polypeptide that is non-naturally occurring in a particular organism, such as a retrovirus or VLP. In some embodiments, a heterologous protein or polypeptide is non-naturally occurring in a particular retrovirus virion. As used herein, the term “heterologous” with respect to a protein domain generally refers to a protein domain that is non- naturally occurring in a particular protein.
  • Immunogenic means capable of producing an immune response in a host animal against a non-host entity (e.g., an HCV antigen). In certain embodiments, this immune response forms the basis of the protective immunity elicited by a vaccine against a specific infectious organism (e.g., an HCV).
  • a non-host entity e.g., an HCV antigen
  • this immune response forms the basis of the protective immunity elicited by a vaccine against a specific infectious organism (e.g., an HCV).
  • Immune response refers to a response elicited in an animal.
  • An immune response may refer to cellular immunity, humoral immunity or may involve both.
  • An immune response may also be limited to a part of the immune system.
  • an immunogenic composition may induce an increased IFNy response.
  • an immunogenic composition may induce a mucosal IgA response (e.g., as measured in nasal and/or rectal washes).
  • an immunogenic composition may induce a systemic IgG response (e.g., as measured in serum).
  • an immunogenic composition may induce virus- neutralizing antibodies or a neutralizing antibody response.
  • an immunogenic composition may induce a CTL response.
  • “reduce,” or grammatical equivalents indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of the treatment described herein.
  • patient refer to a human or a non-human mammalian subject.
  • the individual (also referred to as “patient” or “subject") being treated is an individual (fetus, infant, child, adolescent, or adult) suffering from a disease, for example, HCV infection.
  • the subject is at risk for HCV infection.
  • the subject is an immunosuppressed subject.
  • the immunosuppressed subject is selected from the group consisting of an HIV-infected subject, an AIDS patient, a transplant recipient, a pediatric subject, and a pregnant subject.
  • the subject has been exposed to HCV infection.
  • the subject is a human.
  • Isolated refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from about 10%, about 20%>, about 30%>, about 40%>, about 50%>, about 60%>, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%o, about 97%, about 98%>, about 99%, or more than about 99% of the other components with which they were initially associated.
  • nucleic acid encompasses RNA as well as single and/or double-stranded DNA and/or cDNA.
  • nucleic acid encompasses RNA as well as single and/or double-stranded DNA and/or cDNA.
  • nucleic acid “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, i.e., analogs having other than a phosphodiester backbone.
  • peptide nucleic acids which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention.
  • nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and/or encode the same amino acid sequence. Nucleotide sequences that encode proteins and/or RNA may include introns. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, backbone modifications, etc. A nucleic acid sequence is presented in the 5' to 3' direction unless otherwise indicated.
  • nucleic acid segment is used herein to refer to a nucleic acid sequence that is a portion of a longer nucleic acid sequence. In many embodiments, a nucleic acid segment comprises at least 3, 4, 5, 6, 7, 8, 9, 10, or more residues.
  • amino acids are typically classified as “hydrophobic” or “hydrophilic” amino acids., and/or as having "polar” or “non-polar” side chains Substitution of one amino acid for another of the same type may often be considered a “homologous" substitution.
  • Substantial identity is used herein to refer to a comparison between amino acid or nucleic acid sequences. As will be appreciated by those of ordinary skill in the art, two sequences are generally considered to be “substantially identical” if they contain identical residues in corresponding positions. As is well known in this art, amino acid or nucleic acid sequences may be compared using any of a variety of algorithms, including those available in commercial computer programs such as BLASTN for nucleotide sequences and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul, et al., Basic local alignment search tool, J. Mol.
  • an individual who is "susceptible to" a disease, disorder, or condition is at risk for developing the disease, disorder, or condition.
  • an individual who is susceptible to a disease, disorder, or condition does not display any symptoms of the disease, disorder, or condition.
  • an individual who is susceptible to a disease, disorder, or condition has not been diagnosed with the disease, disorder, and/or condition.
  • an individual who is susceptible to a disease, disorder, or condition is an individual who has been exposed to conditions associated with development of the disease, disorder, or condition (e.g., the individual has been exposed to HCV).
  • Symptoms are reduced: According to the present invention, "symptoms are reduced” when one or more symptoms of a particular disease, disorder or condition is reduced in magnitude (e.g., intensity, severity, etc.) or frequency. For purposes of clarity, a delay in the onset of a particular symptom is considered one form of reducing the frequency of that symptom. It is not intended that the present invention be limited only to cases where the symptoms are eliminated. The present invention specifically contemplates treatment such that one or more symptoms is/are reduced (and the condition of the subject is thereby "improved"), albeit not completely eliminated.
  • HCV hepatitis C virus
  • the body's natural immune response provides a most effective mechanism for terminating viral and many other infections, and for providing protection against new infection.
  • the immune response consists of the humoral response with activated B cells secreting antibody (which can neutralize the infectivity of extracellular virus) and the cellular response, including activated Thl cells (which provide help for the generation of cytotoxic T lymphocytes, CTLs).
  • the Thl response and activated CTLs play the key role in terminating virus infection.
  • the activation of Th2 predominant immune responses is associated with persistence and exacerbation of virus infection.
  • Immunoregulatory molecules including lymphokines that direct T cell differentiation and growth, and cell surface molecules, such as those that provide co- stimulation signals for T cell activation are determining the type of immune response.
  • Retroviruses are enveloped RNA viruses that belong to the family Retroviridae.
  • Retroviral Gag protein alone e.g., lacking a C-terminal extension, lacking one or more of genomic RNA, reverse transcriptase, viral protease, or envelope protein
  • retroviral Gag polyprotein alone can self- assemble to form VLPs both in vitro and in vivo (Sharma S et al., 1997 Proc. Natl. Acad. Sci. USA 94: 10803-8).
  • Retroviral Gag polyprotein alone can oligomerize and assemble into VLPs.
  • a VLP described herein includes an HCV envelope polypeptide, or a portion thereof, that includes a heterologous transmembrane and/or cytoplasmic domain (i.e., that is not found in nature in the HCV envelope polypeptide).
  • a VLP described herein includes an HCV envelope protein variant comprising an extracellular region of an El and/or E2 polypeptide and a heterologous transmembrane domain (or portion thereof) and/or a heterologous cytoplasmic domain (or portion thereof) found in nature in vesicular stomatitis virus (VSV).
  • VSV vesicular stomatitis virus
  • VSV-G functions to target the viral glycoprotein to the cell membrane (Compton T et al, 1989 Proc Natl Acad Sci USA 86:4112-4116).
  • an HCV envelope protein variant comprises or consists of an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:4, or a portion thereof.
  • an HCV envelope protein variant comprises or consists of the amino acid sequence of SEQ ID NO:4, or a portion thereof.
  • a VLP in accordance with the present invention comprises one or more HCV interior non-structural proteins.
  • HCV interior nonstructural proteins include p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B.
  • the p7 protein is dispensable for viral genome replication but plays a critical role in virus morphogenesis.
  • This protein is a 63 amino acid membrane spanning protein which locates itself in the endoplasmic reticulum. Cleavage of p7 is mediated by the endoplasmic reticulum's signal peptidases. Two transmembrane domains of p7 are connected by a cytoplasmic loop and are oriented towards the endoplasmic reticulum's lumen.
  • NS2 protein is 21-23 kiloDalton (kDa) and contains a domain, predicted to interact with the N-terminus of the adjacent NS3 protein. The resulting NS2/3 proteinase is specific for the NS2/NS3 cleavage site. Cleavage at the NS2/NS3 junction is the first
  • NS3 protein is a 70 kDa and consists of two domains; the N-terminal domain has serine protease activity and the C-terminal domain has NTPase/helicase activity (Kim DW. et al., (1995) Biochem Biophys Res Commun 215: 160-166).
  • Serine protease is necessary for HCV infectivity as well as for co- and post-translational cleavage at NS3/4A, NS4A/4B, NS4B/5A and NSB5A/5B sites.
  • the cleavage at NS3/4A site is cis, and all remaining cleavages are trans.
  • RNA helicase in the replication process is not known. Nevertheless NS3 mutations, which alter helicase activity, affect HCV infectivity in vitro. Besides the role in HCV replication and posttranslational editing, the NS3 protein presumably has other functions that interfere with host cell functions.
  • NS5A protein is a hydrophilic phosphoprotein that is bound to membranes and exists in at least 2 forms with molar masses of 56 and 58 kDa. These forms are thought to be the product of different phosphorylation.
  • Recent studies demonstrate that the influence on NS5A phosphorylation is multifactorial, and virtually all NS proteins localized upstream of NS5A are involved (Koch JO. et al, (1999) J Virol 73:7138-7146). It is assumed that NS5A is a component of the HCV replication complex. The kinase responsible for NS5A phosphorylation is probably of cellular origin. Detailed understanding of the role of NS5A protein and NS5A phosphorylation in the process of viral replication is not fully understood.
  • a suitable Gag fusion polypeptide includes a Gag polypeptide that is substantially homologous to a known retroviral Gag polypeptide.
  • a Gag fusion polypeptide may include a modified retroviral Gag polypeptide containing one or more amino acid substitutions, deletions, and/or insertions as compared to a wild-type or naturally-occurring Gag polypeptide (e.g., SEQ ID NO: l), while retaining substantial self-assembly activity.
  • a fusion protein of a Gag and one or more HCV interior nonstructural proteins comprises Gag, NS3, and NS4A (a Gag/NS3-NS4A fusion protein).
  • the NS3 polypeptide consists of or comprises amino acids 539-978 of SEQ ID NO:7 (or a portion thereof).
  • the NS4A polypeptide consists of or comprises amino acids 980-1033 of SEQ ID NO:7 (or a portion thereof)
  • a Gag/NS3-NS4A fusion protein comprises or consists of an amino acid sequence that is substantially homologous to SEQ ID NO:7, or a portion thereof.
  • a Gag/NS3-NS4A fusion protein comprises or consists of an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO:7, or a portion thereof.
  • VLPs containing a structural component of a virus e.g., MLV, e.g., MMLV
  • one or more heterologous surface antigens e.g., HCV envelope protein
  • El and/or E2 envelope protein or an El and/or E2 envelope protein variant (or a portion thereof) described herein.
  • the variant includes an extracellular domain of an El and/or E2 polypeptide, a transmembrane domain found in VSV-G, and a cytoplasmic domain found in VSV-G.
  • an El, El variant, E2, and/or E2 variant is incorporated into the VLP and serves as an antigen for eliciting an immune response against HCV.
  • VLPs containing a structural component (e.g., a Gag polypeptide) of a virus (e.g., MLV, e.g., MMLV) joined to (e.g., fused to) one or more heterologous antigens (e.g., one or more HCV interior nonstructural proteins) are effective for antigen delivery and induction of an immune response against the heterologous antigen.
  • a structural component e.g., a Gag polypeptide
  • a virus e.g., MLV, e.g., MMLV
  • heterologous antigens e.g., one or more HCV interior nonstructural proteins
  • a Gag polypeptide is expressed as a fusion protein with a heterologous HCV antigen (e.g., one or more HCV interior non-structural proteins or portion thereof).
  • a heterologous HCV antigen e.g., one or more HCV interior non-structural proteins or portion thereof.
  • a coding sequence for one or more heterologous HCV interior nonstructural proteins may be spliced into the Gag polypeptide coding sequence, e.g., at the 3' end of the Gag polypeptide coding sequence.
  • a coding sequence for one or more HCV interior non-structural proteins may be spliced in frame into the Gag polypeptide coding sequence.
  • a Gag polypeptide-coding sequence and a coding sequence for one or more HCV interior non-structural proteins may be expressed by a single promoter.
  • one or more HCV interior non-structural proteins is inserted at (e.g., fused to) the C-terminus of a Gag polypeptide.
  • fusion of a self-assembling Gag polypeptide to a heterologous HCV antigen e.g., HCV interior non-structural protein
  • HCV antigen e.g., HCV interior non-structural protein
  • Provided VLPs may contain a structural retroviral protein (e.g., Gag polypeptide) that is arranged and constructed such that it self-assembles to form the VLP and is positioned in the VLP interior.
  • a structural retroviral protein e.g., Gag polypeptide
  • provided VLPs contain an HCV envelope protein (e.g., El and/or E2, or an El and/or E2 envelope variant protein) that is arranged and constructed such that one or more epitopes of the HCV envelope protein (e.g., El and/or E2, or an El and/or E2 envelope variant protein) is positioned on the VLP surface.
  • provided VLPs contain a fusion of a Gag polypeptide and an HCV interior non-structural protein (e.g., a Gag-NS3 and/or NS4A fusion protein) that is arranged and constructed such that one or more epitopes of the HCV interior protein (e.g., NS3 and/or NS4A) is positioned in the VLP interior.
  • provided VLPs contain (i) a fusion of a Gag polypeptide and an HCV interior non-structural protein (e.g., a Gag/NS3 and/or NS4A fusion protein) and (ii) an HCV envelope protein or HCV envelope protein variant described herein.
  • a composition comprising VLPs can typically include a mixture of VLPs with a range of sizes. It is to be understood that the diameter values listed below correspond to the most frequent diameter within the mixture. In some embodiments > 90% of the vesicles in a composition will have a diameter which lies within 50% of the most frequent value (e.g., 1000 ⁇ 500 nm). In some embodiments the distribution may be narrower, e.g., > 90%) of the vesicles in a composition may have a diameter which lies within 40, 30, 20, 10 or 5% of the most frequent value. In some embodiments, sonication or ultra-sonication may be used to facilitate VLP formation and/or to alter VLP size. In some embodiments, filtration, dialysis and/or centrifugation may be used to adjust the VLP size distribution.
  • VLPs produced in accordance with the methods of the present disclosure may be of any size.
  • the composition may include VLPs with diameter in range of about 20 nm to about 300 nm.
  • a VLP is
  • VLPs within a population show an average diameter within a range bounded by a lower limit of 20, 30, 40, 50, 60, 70, 80, 90, or 100 nm and bounded by an upper limit of 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, or 170 nm.
  • VLPs within a population show an average diameter within a range bounded by a lower limit of 20, 30, 40, 50, 60, 70, 80, 90, or 100 nm and bounded by an upper limit of 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, or 170 nm.
  • VLPs in a population have a polydispersity index that is less than 0.5 (e.g., less than 0.45, less than 0.4, or less than 0.3).
  • VLP diameter is determined by nanosizing. In some embodiments, VLP diameter is determined by electron microscopy.
  • VLPs are prepared using one or more nucleotide sequences of SEQ ID NO:2, 5, or 8. In some embodiments, VLPs are prepared using one or more nucleotide sequences substantially homologous to SEQ ID NO:2, 5, or 8. In some embodiments, VLPs are prepared using one or more nucleotide sequences that are at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) or more homologous to SEQ ID NO:2, 5, or 8.
  • VLPs are prepared using nucleotide sequences that are codon optimized. Codon optimization is well known in the art and involves modification of codon usage so that higher levels of protein are produced. In some embodiments, VLPs are prepared using one or more nucleotide sequences of SEQ ID NO:3, 6, or 9. In some
  • VLPs are prepared using one or more nucleotide sequences substantially homologous to SEQ ID NO:3, 6, or 9. In some embodiments, VLPs are prepared using one or more nucleotide sequences that are at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO:3, 6, or 9. In some embodiments, VLPs are prepared using one or more nucleotide sequences substantially identical to SEQ ID NO:3, 6, or 9.
  • VLPs are prepared using one or more nucleotide sequences that are at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:3, 6, or 9.
  • VLPs may be prepared according to techniques known in the art. For example, in some embodiments, provided VLPs may be produced in any available protein expression system. Typically, the expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce VLPs. In some embodiments, VLPs are produced using transient transfection of cells. In some embodiments, VLPs are produced using stably transfected cells.
  • Typical cell lines that may be utilized for VLP production include, but are not limited to, mammalian cell lines such as human embryonic kidney (HEK) 293, WI 38, Chinese hamster ovary (CHO), monkey kidney (COS), HT1080, CIO, HeLa, baby hamster kidney (BHK), 3T3, CI 27, CV-1, HaK, NS/O, and L-929 cells.
  • mammalian cell lines such as human embryonic kidney (HEK) 293, WI 38, Chinese hamster ovary (CHO), monkey kidney (COS), HT1080, CIO, HeLa, baby hamster kidney (BHK), 3T3, CI 27, CV-1, HaK, NS/O, and L-929 cells.
  • BALB/c mouse myeloma line NSO/1, ECACC No: 85110503
  • human retinoblasts PER.C6 (CruCell, Leiden, The Netherlands)
  • monkey kidney CV1 line transformed by SV40 COS-7, ATCC CRL 1651
  • human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al, J. Gen Virol, 36:59 (1977)
  • baby hamster kidney cells BHK, ATCC CCL 10
  • Chinese hamster ovary cells +/-DHFR CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci.
  • mice Sertoli cells TM4, Mather, Biol. Reprod., 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL- 1 587); human cervical carcinoma cells (HeLa, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al, Annals N. Y. Acad.
  • cell lines that may be utilized for VLP production include insect (e.g., Sf-9, Sf-21, Hi5) or plant (e.g.,
  • leguminosa, cereal, or tobacco cells are preferable for protein expression and/or VLP production (see, e.g., Roldao A et al, 2010 Expt Rev Vaccines 9: 1149- 76).
  • a cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific way. Such modifications (e.g., glycosylation) and processing (e.g., cleavage or transport to the membrane) of protein products may be important for generation of a VLP or function of a VLP polypeptide or additional polypeptide (e.g., an adjuvant or additional antigen).
  • modifications e.g., glycosylation
  • processing e.g., cleavage or transport to the membrane
  • Different cells have characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.
  • eukaryotic host cells also referred to as packaging cells (e.g., 293T human embryo kidney cells) which possess appropriate cellular machinery for proper processing of the primary transcript, glycosylation and phosphorylation of the gene product may be used in accordance with the present invention.
  • packaging cells e.g., 293T human embryo kidney cells
  • VLPs may be purified according to known techniques, such as centrifugation, gradients, chromatography (e.g., ion exchange, affinity and sizing column chromatography), or differential solubility, among others. Alternatively or additionally, cell supernatant may be used directly, with no purification step. Additional entities, such as additional antigens or adjuvants may be added to purified VLPs. In vivo VLP Production
  • VLPs in accordance with the present invention may be prepared as DNA vaccines according to methods well known in the art.
  • one or more vectors or plasmids e.g., such as those described above, is administered to a subject such that recipient cells express polypeptides encoded by the vector or plasmid.
  • recipient cells expressing such polypeptides produce VLPs comprising the polypeptides.
  • cells may be transfected with a single expression vector as described herein.
  • a single expression vector encodes more than one element of a VLP (e.g., more than one of structural polyprotein, HCV interior non- structural protein, HCV glycoprotein, etc.).
  • cells may be transfected with a single expression vector that encodes a retroviral Gag polypeptide described herein and one or more HCV interior nonstructural proteins and/or one or more HCV envelope proteins.
  • a single expression vector encodes two or more elements of a HCV VLP.
  • a single expression vector encodes three or more elements of a HCV VLP.
  • cells may be transfected with one or more expression vectors.
  • cells may be transfected with a vector encoding a Gag/NS3-NS4A fusion polypeptide.
  • "bivalent" HCV VLPs comprising two HCV interior non-structural proteins (NS3 and NS4A) are produced.
  • cells may be transfected with two or more expression vectors.
  • cells may be transfected with a first vector encoding a retroviral Gag polypeptide and a second vector encoding an HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G).
  • HCV envelope protein e.g., El or E2
  • HCV envelope protein variant e.g., E2-G
  • "monovalent" HCV VLPs comprising an HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G) are produced.
  • cells are transfected with a first vector encoding a retroviral Gag polypeptide, a second vector encoding an HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G) and a third vector encoding another HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G).
  • HCV envelope protein e.g., El or E2
  • E2-G HCV envelope protein variant
  • "bivalent" HCV VLPs comprising two HCV envelope proteins (e.g., El and E2) or HCV envelope protein variants (e.g., E2-G) are produced.
  • cells are transfected with a first vector encoding a fusion protein of a Gag polypeptide and one or more HCV interior non-structural protein described herein and a second vector encoding an HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G).
  • HCV envelope protein e.g., El or E2
  • HCV envelope protein variant e.g., E2-G
  • cells are transfected with a first vector encoding a Gag/NS3-NS4A fusion polypeptide, and a second vector encoding an HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G).
  • HCV envelope protein e.g., El or E2
  • HCV envelope protein variant e.g., E2-G
  • cells are transfected with a first vector encoding a Gag/NS3-NS4A fusion polypeptide, a second vector encoding an HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G), and a third vector encoding another HCV envelope protein (e.g., El or E2) or an HCV envelope protein variant (e.g., E2-G).
  • HCV envelope protein e.g., El or E2
  • E2-G HCV envelope protein variant
  • "quadrivalent" HCV VLPs comprising two HCV interior non-structural proteins (NS3 and NS4A) and two HCV envelope proteins (e.g., El and E2) or HCV envelope protein variants (e.g., E2-G) are produced.
  • monovalent, bivalent, trivalent, and/or quadrivalent HCV monovalent, bivalent, trivalent, and/or quadrivalent HCV
  • VLPs are admixed.
  • monovalent and bivalent HCV VLPs are admixed to form a trivalent HCV VLP mixture.
  • two bivalent HCV VLPs are admixed to form a trivalent HCV VLP mixture.
  • compositions comprising provided
  • VLPs and/or provided glycoprotein variants are provided.
  • the present invention provides a VLP and at least one pharmaceutically acceptable excipient.
  • Such pharmaceutical compositions may optionally comprise and/or be administered in combination with one or more additional therapeutically active substances.
  • provided pharmaceutical compositions are useful in medicine.
  • provided pharmaceutical compositions are useful as prophylactic agents (i.e., vaccines) in the treatment or prevention of HCV or of negative ramifications associated or correlated with HCV infection.
  • provided pharmaceutical compositions are useful in therapeutic applications, for example in individuals suffering from or susceptible to HCV infection.
  • pharmaceutical compositions are formulated for administration to humans.
  • compositions provided here may be provided in a sterile injectible form (e.g., a form that is suitable for subcutaneous injection or intravenous infusion).
  • a sterile injectible form e.g., a form that is suitable for subcutaneous injection or intravenous infusion.
  • pharmaceutical compositions are provided in a liquid dosage form that is suitable for injection.
  • pharmaceutical compositions are provided as powders (e.g. lyophilized and/or sterilized), optionally under vacuum, which are reconstituted with an aqueous diluent (e.g., water, buffer, salt solution, etc.) prior to injection.
  • an aqueous diluent e.g., water, buffer, salt solution, etc.
  • compositions are diluted and/or reconstituted in water, sodium chloride solution, sodium acetate solution, benzyl alcohol solution, phosphate buffered saline, etc.
  • powder should be mixed gently with the aqueous diluent (e.g., not shaken).
  • provided pharmaceutical compositions comprise one or more pharmaceutically acceptable excipients (e.g., preservative, inert diluent, dispersing agent, surface active agent and/or emulsifier, buffering agent, etc.).
  • suitable excipients include, for example, water, saline, dextrose, sucrose, trehalose, glycerol, ethanol, or similar, and
  • the vaccine may contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines.
  • pharmaceutical compositions comprise one or more preservatives. In some embodiments, pharmaceutical compositions comprise no preservative.
  • compositions are provided in a form that can be refrigerated and/or frozen. In some embodiments, pharmaceutical compositions are provided in a form that cannot be refrigerated and/or frozen. In some embodiments, reconstituted solutions and/or liquid dosage forms may be stored for a certain period of time after reconstitution (e.g., 2 hours, 12 hours, 24 hours, 2 days, 5 days, 7 days, 10 days, 2 weeks, a month, two months, or longer). In some embodiments, storage of VLP formulations for longer than the specified time results in VLP degradation.
  • Liquid dosage forms and/or reconstituted solutions may comprise particulate matter and/or discoloration prior to administration.
  • a solution should not be used if discolored or cloudy and/or if particulate matter remains after filtration.
  • Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology.
  • such preparatory methods include the step of bringing active ingredient into association with one or more excipients and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
  • a pharmaceutical composition in accordance with the invention may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
  • a "unit dose" is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to a dose which would be administered to a subject and/or a convenient fraction of such a dose such as, for example, one-half or one -third of such a dose.
  • Relative amounts of active ingredient, pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the invention may vary, depending upon the identity, size, and/or condition of the subject treated and/or depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100% (w/w) active ingredient.
  • compositions of the present invention may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, may be or comprise solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable excipient which, as used herein, may be or comprise solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro, discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof.
  • a pharmaceutical composition is sufficiently immunogenic as a vaccine (e.g., in the absence of an adjuvant).
  • immunogenicity of a pharmaceutical composition is enhanced by including an adjuvant.
  • Any adjuvant may be used in accordance with the present invention. A large number of adjuvants are known; a useful compendium of many such compounds is prepared by the National Institutes of Health and can be found (www.niaid.nih.gov/daids/vaccine/pdf/compendium.pdf). See also Allison (1998, Dev. Biol. Stand., 92:3-11; incorporated herein by reference), Unkeless et al. (1998, Annu. Rev.
  • adjuvants include, but are not limited to, cytokines, gel-type adjuvants (e.g., aluminum hydroxide, aluminum phosphate, calcium phosphate, etc.); microbial adjuvants (e.g., immunomodulatory DNA sequences that include CpG motifs; endotoxins such as monophosphoryl lipid A; exotoxins such as cholera toxin, E.
  • cytokines e.g., cytokines
  • gel-type adjuvants e.g., aluminum hydroxide, aluminum phosphate, calcium phosphate, etc.
  • microbial adjuvants e.g., immunomodulatory DNA sequences that include CpG motifs
  • endotoxins such as monophosphoryl lipid A
  • exotoxins such as cholera toxin, E.
  • oil-emulsion and emulsifier-based adjuvants e.g., Freund's Adjuvant, MF59 [Novartis], SAF, etc.
  • particulate adjuvants e.g., liposomes, biodegradable microspheres, saponins, etc.
  • synthetic adjuvants
  • exemplary adjuvants include some polymers (e.g., polyphosphazenes; described in U.S. Patent 5,500,161, which is incorporated herein by reference), Q57, QS21, squalene, tetrachlorodecaoxide, etc.
  • pharmaceutically acceptable excipients have been previously described in further detail in the above section entitled “Pharmaceutical Compositions.” Administration
  • compositions and methods of the present disclosure are useful for prophylaxis of HCV and/or therapeutic treatment of HCV infection in a subject, including human adults and children. In general however they may be used with any animal. In certain embodiments, the methods herein may be used for veterinary applications, e.g., canine and feline applications. If desired, the methods herein may also be used with farm animals, such as ovine, avian, bovine, porcine and equine breeds.
  • the terms "subject,” “individual” or “patient” refer to a human or a non-human mammalian subject.
  • the individual (also referred to as “patient” or “subject") being treated is an individual (fetus, infant, child, adolescent, or adult) suffering from a disease, for example, HCV infection.
  • the subject is at risk for HCV infection.
  • the subject is an immunosuppressed subject.
  • the immunosuppressed subject is selected from the group consisting of an HIV- infected subject, an AIDS patient, a transplant recipient, a pediatric subject, and a pregnant subject.
  • the subject has been exposed to HCV infection.
  • the subject is a human.
  • compositions described herein will generally be administered in such amounts and for such a time as is necessary or sufficient to induce an immune response.
  • Dosing regimens may consist of a single dose or a plurality of doses over a period of time.
  • the exact amount of an immunogenic composition (e.g., VLP) to be administered may vary from subject to subject and may depend on several factors. Thus, it will be appreciated that, in general, the precise dose used will be as determined by the prescribing physician and will depend not only on the weight of the subject and the route of administration, but also on the age of the subject and the severity of the symptoms and/or the risk of infection. In certain embodiments a particular amount of a VLP composition is administered as a single dose.
  • a particular amount of a VLP composition is administered as more than one dose (e.g., 1-3 doses that are separated by 1-12 months). In certain embodiments a particular amount of a VLP composition is administered as a single dose on several occasions (e.g., 1-3 doses that are separated by 1-12 months). [0127] In some embodiments, a provided composition is administered in an initial dose and in at least one booster dose. In some embodiments, a provided composition is administered in an initial dose and two booster doses. In some embodiments, a provided composition is administered in an initial dose and three booster doses. In some embodiments, a provided composition is administered in an initial dose and four booster doses.
  • a provided composition is administered in an initial dose and in at least one booster dose about one month, about two months, about three months, about four months, about five months, or about six months following the initial dose.
  • a provided composition is administered in a second booster dose about six months, about seven months, about eight months, about nine months, about ten months, about eleven months, or about one year following the initial dose.
  • a provided composition is administered in a booster dose every 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years.
  • compositions may be formulated for delivery parenterally, e.g., by injection.
  • administration may be, for example, intravenous, intramuscular, intradermal, or subcutaneous, or via by infusion or needleless injection techniques.
  • the compositions may be formulated for peroral delivery, oral delivery, intranasal delivery, buccal delivery, sublingual delivery, transdermal delivery, transcutaneous delivery, intraperitoneal delivery, intravaginal delivery, rectal delivery or intracranial delivery.
  • a standard expression plasmid generally consists of a promoter sequence of mammalian origin, an intron sequence, a PolyAdenylation signal sequence (Poly A), a pUC origin of replication sequence (pUC - pBR322 is a colEl origin/site of replication initiation and is used to replicate plasmid in bacteria such as E Coli (DH5 )), and an antibiotic resistance gene as a selectable marker for plasmid plaque selection.
  • Within the plasmid following the Intron are a variety of restriction enzyme sites that can be used to splice in a gene or partial gene sequence of interest.
  • the Propol II expression plasmid contains the pHCMV (early promoter for
  • HCMV Beta-Globin Intron
  • BGL Intron Beta-Globin Intron
  • Poly A rabbit Globin polyAdenylation signal sequence
  • pUC - pBR322 is a colEl origin/site of replication initiation and is used to replicate plasmid in bacteria such as E. coli (DH5a)
  • An ampicillin resistance gene ⁇ -lactamase Amp R - selectable marker for plasmid confers resistance to ampicillin (100 ⁇ g/ml) ( Figure 1A).
  • Figure IB depicts exemplary recombinant expression plasmids.
  • Gag/NS3-NS4A a sequence encoding the Gag polyprotein of MMLV (Gag without its C terminus Pol sequence) was fused with the truncated NS3 sequence corresponding to the helicase domain of HCV NS3 and HCV NS4A sequence, codon-optimized for human expression (GenScript) and cloned into a Propol II expression vector ( Figure 2).
  • a complementary DNA (cDNA) sequence encoding a Gag polyprotein of MMLV (Gag without its C terminus Pol sequence) was cloned into a Propol II (pHCMV) expression vector.
  • pHCMV Propol II
  • E2-G E2-G expression construct
  • Poly A polyAdenylation signal sequence
  • DNA plasmids were amplified in competent E. coli (DH5a) and purified with endotoxin- free preparation kits according to standard protocols. Description of the Gag/NS3-NS4A Fusion Gene Sequence:
  • the different sequences comprising the Gag/NS3-NS4A fusion nucleotide sequence are shown in Table 1.
  • the Gag_ is a sequence corresponding to the full length sequence of the Moloney Murine Leukemia Virus Gag without its C terminus Pol sequence, corresponding to base pairs 357-1971 from GenBank accession number AF033811.1.
  • the HCV NS3 helicase is the HCV NS3 helicase sequence, corresponding to base pairs 3989- 5323 from the JFHl isolate sequence, GenBank AB047639.
  • the HCV NS4A is the HCV NS4A domain, corresponding to base pairs 5324-5485 from the JFHl isolate sequence, GenBank
  • Gag/NS3-NS4A sequence was codon optimized (SEQ ID NO:9) to maximize protein expression in human cells. For subcloning purposes, additional 3 '(GAATTCCACGTGGGATCC) and 5'(CTCGAGGTTTAAACGAATTCCGCCACC) sequences containing restriction sites were added. The Gag/NS3-NS4A fusion sequence was subcloned into the expression plasmid Propol II, in cloning sites XhoI-BamHI ( Figure 2).
  • the HCV deltaCorejs a sequence corresponding to a fragment of the core of hepatitis C virus, corresponding to base pairs 740-913 from JFHl isolate, GenBank accession number AB047639.
  • the HCV E2 extracellular (without TM/Cyt) is an E2 sequence deprived of transmembrane and cytoplasmic domains, corresponding to JFHl isolate sequence base pairs 1489-2344.
  • the VSV-G TM/Cyt is the transmembrane and cytoplasmic domain of the glycoprotein G from the vesicular stomatitis virus, strain Indiana, GenBank accession number J02428, corresponding to base pairs 2821-2955.
  • the E2-G gene sequence was codon optimized (SEQ ID NO:6) to maximize protein expression in human cells.
  • SEQ ID NO:6 A rabbit Globin polyAdenylation signal sequence (poly A) was synthesized directly after the optimized sequence for HCV E2-G and additional 3 ' (G AATTCC ACGTGGGATCC) and
  • This Example describes methods for production of virus-like particles containing various recombinant HCV antigens described in Example 1.
  • HEK 293T cells (ATCC, CRL-11268) were transiently transfected using calcium phosphate methods with an MMLV-Gag DNA expression plasmid and co-transfected with an E2-G DNA expression plasmid.
  • cells were transfected with a Gag/NS3-NS4A DNA expression plasmid and co-transfected with an E2-G DNA expression plasmid (Table 3).
  • MMLV-Gag content in different eVLP preparations was quantified using a commercially available Quick Titer MuLV Core Antigen ELISA kit (MuLV p30) (Cell Biolabs, Cat# VPK-156) according to the manufacturer's instructions. All monovalent E2-G VLPs and bivalent E2-G and Gag/NS3-NS4A VLPs had significant Gag content and post transfection HEK 293 cell preparations exhibited surface- staining for E2 providing indirect evidence that E2-G was being expressed and directed to the VLP envelope [see Table 4].
  • Purified eVLPs were stored at -20°C until used. Each lot of purified eVLPs was analyzed for the expression of MMLV-Gag, E2-G and/or MMLV-Gag/NS3-NS4A fusion protein by SDS-Page ( Figure 5) and Western Blot with specific antibodies to Gag ( Figure 6; Primary antibody Anti-MuLV p30 rat monoclonal antibody , R187, ATCC CRL-1912; Secondary antibody Goat anti-rat alkaline phosphatase ), E2-G ( Figure 7; Primary antibody mouse monoclonal antibody to Anti-VSV-G tag antibody P5D4, Sigma V5507; Secondary antibody Goat anti-mouse alkaline phosphatase).
  • E2-G detection on western blots we also used specific monkey serum from monkeys primed with an Adenovirus expressing E1E2 followed by a boost with E1E2 VLPs which should result in an increased titer of neutralizing antibodies to both El and E2 in the treated monkeys sera which could then be used to detect portions of the native E2 sequence of E2-G in a western blot, data not shown) .
  • secondary antibodies with alkaline phosphatase were detected by combination with NBT and BCIP as chromogenic substrates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des procédés utiles pour le traitement de l'infection par le HVC. Tel que ceci est décrit dans le présent document, les compositions et les procédés sont basés sur la mise au point de compositions immunogènes qui comprennent des particules pseudovirales (VLP) qui comprennent au moins une protéine de noyau du virus de la leucémie murine de Moloney (MMLV) et comprennent au moins un épitope du HCV, comme, par exemple, la glycoprotéine d'enveloppe du HCV E1 et/ou E2 ou leurs variants (par exemple, E2G) et/ou des protéines non structurelles NS3 et/ou NS4A. Entre autres, la présente invention comprend la reconnaissance du fait qu'une combinaison d'antigènes (par exemple, des glycoprotéines d'enveloppe et des protéines non structurelles intérieures) peuvent conduire à des réponses immunitaires bénéfiques, par exemple qui comprennent à la fois une réponse humorale (par exemple, la production d'anticorps neutralisants) et une réponse cellulaire (par exemple, l'activation des lymphocytes T).
PCT/IB2014/000815 2013-02-25 2014-02-25 Compositions et procédés destinés au traitement de l'hépatite c Ceased WO2014128568A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361769140P 2013-02-25 2013-02-25
US61/769,140 2013-02-25
US201361803940P 2013-03-21 2013-03-21
US61/803,940 2013-03-21

Publications (2)

Publication Number Publication Date
WO2014128568A2 true WO2014128568A2 (fr) 2014-08-28
WO2014128568A3 WO2014128568A3 (fr) 2014-12-04

Family

ID=51391928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/000815 Ceased WO2014128568A2 (fr) 2013-02-25 2014-02-25 Compositions et procédés destinés au traitement de l'hépatite c

Country Status (1)

Country Link
WO (1) WO2014128568A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015128731A3 (fr) * 2014-02-25 2015-12-17 Variation Biotechnologies, Inc. Compositions et méthodes pour le traitement de l'hépatite c
WO2017157437A1 (fr) 2016-03-16 2017-09-21 Institut Curie Procédé de préparation de particules virales à dinucléotide cyclique et utilisation desdites particules pour le traitement du cancer
WO2018014113A1 (fr) 2016-07-18 2018-01-25 Variation Biotechnologies Inc. Compositions vaccinales pour le traitement d'une infection par le virus zika
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
US10273285B2 (en) 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
JP2023519837A (ja) * 2020-03-30 2023-05-15 ヴァリエーション バイオテクノロジーズ インコーポレイテッド コロナウイルスを処置するためのワクチン組成物
WO2025257403A1 (fr) * 2024-06-14 2025-12-18 Dotbio Pte. Ltd. Particules pseudo-virales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537206B1 (fr) * 2002-09-13 2009-05-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pseudo-particules d'hepacivirus infectieuses renfermant des proteines fonctionnelles d'enveloppe e1, e2

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015128731A3 (fr) * 2014-02-25 2015-12-17 Variation Biotechnologies, Inc. Compositions et méthodes pour le traitement de l'hépatite c
US10273285B2 (en) 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
WO2017157437A1 (fr) 2016-03-16 2017-09-21 Institut Curie Procédé de préparation de particules virales à dinucléotide cyclique et utilisation desdites particules pour le traitement du cancer
EP3770265A1 (fr) 2016-03-16 2021-01-27 Institut Curie Procédé de préparation de particules virales à dinucléotide cyclique et utilisation desdites particules pour le traitement du cancer
WO2018014113A1 (fr) 2016-07-18 2018-01-25 Variation Biotechnologies Inc. Compositions vaccinales pour le traitement d'une infection par le virus zika
EP3484511A4 (fr) * 2016-07-18 2020-04-29 Variation Biotechnologies Inc. Compositions vaccinales pour le traitement d'une infection par le virus zika
EP4039272A1 (fr) * 2016-07-18 2022-08-10 Variation Biotechnologies Inc. Compositions de vaccin pour le traitement du virus zika
AU2017298576B2 (en) * 2016-07-18 2023-04-13 Variation Biotechnologies Inc. Vaccine compositions for treatment of Zika virus
JP2023519837A (ja) * 2020-03-30 2023-05-15 ヴァリエーション バイオテクノロジーズ インコーポレイテッド コロナウイルスを処置するためのワクチン組成物
EP4126038A4 (fr) * 2020-03-30 2024-04-17 Variation Biotechnologies Inc. Compositions de vaccin pour le traitement du coronavirus
WO2025257403A1 (fr) * 2024-06-14 2025-12-18 Dotbio Pte. Ltd. Particules pseudo-virales

Also Published As

Publication number Publication date
WO2014128568A3 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
US12421283B2 (en) Compositions and methods for treatment of cytomegalovirus
CA3174215A1 (fr) Vaccin contre un coronavirus
WO2014128568A2 (fr) Compositions et procédés destinés au traitement de l'hépatite c
CA3176481A1 (fr) Vaccin contre le coronavirus
US11253587B2 (en) Vaccine compositions for the treatment of coronavirus
CA2982796C (fr) Compositions de vaccin destinees au traitement du virus zika
WO2025106754A1 (fr) Vaccin anti-coronavirus
US20240366753A1 (en) Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus
WO2015128731A2 (fr) Compositions et méthodes pour le traitement de l'hépatite c
US20220233682A1 (en) Vaccine compositions for the treatment of coronavirus
CN116457011A (zh) 用于治疗冠状病毒的疫苗组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14753821

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14753821

Country of ref document: EP

Kind code of ref document: A2